Q-omics provides the consensus-scored TGM6 profile across patient tissues and cancer cell-line models. TGM6 expression is associated with patient survival in 13 of 34 cancer types, with the highest sampling consensus in LUAD. Among the 18 cancer types available for tumor–normal comparison, TGM6 is differentially expressed in 5, with the highest sampling consensus in LUSC. Additionally, TGM6 RNA expression shows 6,638 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight LUAD, LUSC, and STAD as cancer lineages where TGM6 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TGM6 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TGM6 survival associations across molecular data types. TGM6 RNA expression shows survival associations in the most cancer types (13), followed by mutation status (8). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TGM6 RNA expression–survival associations across cancer types. High TGM6 expression shows unfavorable associations in LUAD, UVM, KIRC, PAAD and COAD, but favorable associations in CESC. The LUAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LUAD as the clearest survival context for TGM6 RNA expression.
This table summarizes TGM6 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5. The strongest signals are observed in LUSC for RNA.
This table ranks reproducible tumor–normal expression differences for TGM6. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TGM6 shows lower tumor expression in COAD and higher tumor expression in LUSC, UCEC, PRAD and KIRC. The LUSC box plot shows higher TGM6 RNA expression in tumor versus normal tissue (log2 FC = +0.292, t-test p = .001).
This table shows molecular features associated with TGM6 in patient tissues and cancer cell lines. In patient samples, TGM6 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set. In cancer cell lines, TGM6 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and LARGE_INTESTINE.
